FDA Brief

Warning letters Food

FDA warning letter to

Live Good Inc.

High riskIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

Live Good Inc. sold Berry Gen Sugar Control supplements as a diabetes treatment without FDA approval, making it an unapproved, misbranded drug.

What happened

FDA reviewed the company's website (berrygen.com), its linked Facebook and Instagram pages, and its Amazon storefront in August 2021, and the Federal Trade Commission reviewed the websites at the same time. FDA found claims that Berry Gen Sugar Control reduces blood sugar, controls glucose, regulates insulin, protects the pancreas and helps control diabetes. FDA says these claims make the supplement a drug, and one sold without approval and without adequate directions for use.

What FDA found

  1. The website, social media and Amazon claims that the product treats or prevents diabetes and controls blood sugar show it is intended as a drug.

    Federal Food, Drug, and Cosmetic Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The product is not generally recognized as safe and effective for these uses, so it is a new drug sold without FDA approval.

    Sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product does not carry adequate directions for use, because treating diabetes safely needs a licensed practitioner.

    Section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 C.F.R. 201.5
  4. Shipping this misbranded drug across state lines violates the Act.

    Section 301(a) [21 U.S.C. 331(a)]
  5. The FTC says the diabetes treatment claims are not backed by competent and reliable scientific evidence, such as well-controlled human clinical studies.

    FTC Act, 15 U.S.C. ยง 45

What FDA wants

Write to FDA within 15 working days describing each step taken to fix the violations and prevent them from recurring, with supporting documents, or explain why more time is needed. The FTC separately asks for notice within 15 working days of actions taken on the advertising claims.

Who should pay attention

  • dietary supplement brands making blood sugar or diabetes claims
  • Amazon sellers and marketplace listing teams
  • marketers running social media ads, including in Spanish

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk